| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Gemcitabine | gCSI | pan-cancer | AAC | 0.28 | 3e-07 |
| mRNA | Methotrexate | CTRPv2 | pan-cancer | AAC | 0.18 | 1e-06 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | 0.23 | 9e-06 |
| mRNA | temsirolimus | GDSC1000 | pan-cancer | AAC | 0.15 | 2e-05 |
| mRNA | neratinib | CTRPv2 | pan-cancer | AAC | -0.16 | 2e-05 |
| mRNA | STF-31 | CTRPv2 | pan-cancer | AAC | 0.15 | 4e-05 |
| mRNA | niclosamide | CTRPv2 | pan-cancer | AAC | 0.14 | 0.0001 |
| mRNA | selumetinib:navitoclax (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.14 | 0.0002 |
| mRNA | austocystin d | CTRPv2 | pan-cancer | AAC | -0.14 | 0.0002 |
| mRNA | WZ4002 | CTRPv2 | pan-cancer | AAC | -0.16 | 0.0003 |